Michael S Diamond Selected Research

Zika Virus Infection

10/2020	Antibodies targeting epitopes on the cell-surface form of NS1 protect against Zika virus infection during pregnancy.
9/2020	Intramuscular Delivery of Replicon RNA Encoding ZIKV-117 Human Monoclonal Antibody Protects against Zika Virus Infection.
3/2020	Author Correction: Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection.
1/2020	Zika Virus Targets Glioblastoma Stem Cells through a SOX2-Integrin αvβ5 Axis.
10/2019	Protective Efficacy of Nucleic Acid Vaccines Against Transmission of Zika Virus During Pregnancy in Mice.
1/2019	Interferon lambda protects the female reproductive tract against Zika virus infection.
1/2018	Cross-reactive Dengue virus-specific CD8+ T cells protect against Zika virus during pregnancy.
1/2018	Cellular and Humoral Immunity Protect against Vaginal Zika Virus Infection in Mice.
11/2017	Dengue virus-reactive CD8+ T cells mediate cross-protection against subsequent Zika virus challenge.
11/2017	Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael S Diamond Research Topics

Disease

231	Infections 12/2022 - 12/2002
76	West Nile Fever 10/2021 - 12/2003
57	Virus Diseases (Viral Diseases) 01/2022 - 12/2002
53	COVID-19 12/2022 - 01/2020
23	Dengue (Dengue Fever) 11/2021 - 12/2002
22	Inflammation (Inflammations) 10/2022 - 02/2008
21	Zika Virus Infection 10/2020 - 01/2016
16	Flavivirus Infections 01/2021 - 12/2002
11	Encephalitis (Encephalitis, Rasmussen) 01/2021 - 11/2006
11	Viremia 01/2020 - 12/2003
11	Arthritis (Polyarthritis) 01/2020 - 12/2013
10	Vesicular Stomatitis 01/2022 - 01/2012
7	Weight Loss (Weight Reduction) 02/2022 - 01/2020
7	Coinfection 01/2021 - 09/2010
6	Neoplasms (Cancer) 11/2021 - 11/2018
6	Yellow Fever 12/2020 - 05/2008
5	Breakthrough Infections 02/2022 - 08/2021
5	Alphavirus Infections 01/2021 - 01/2018
5	Japanese Encephalitis 11/2020 - 05/2008
5	Severe Dengue 01/2012 - 12/2007
4	Pneumonia (Pneumonitis) 02/2022 - 12/2020
4	Human Influenza (Influenza) 01/2022 - 09/2003
4	Communicable Diseases (Infectious Diseases) 05/2021 - 01/2014
4	Bites and Stings (Sting) 10/2020 - 07/2012
3	Coronavirus Infections 01/2022 - 12/2020
3	Lung Diseases (Lung Disease) 12/2020 - 07/2020
3	Persistent Infection 01/2020 - 01/2016
3	Melanoma (Melanoma, Malignant) 01/2017 - 05/2006
3	Thrombocytopenia (Thrombopenia) 09/2015 - 02/2010
2	Weight Gain 01/2022 - 06/2021
2	Zoonoses 01/2022 - 12/2021
2	Glioblastoma (Glioblastoma Multiforme) 11/2021 - 10/2017
2	Severe Acute Respiratory Syndrome 04/2021 - 01/2021

Drug/Important Bio-Agent (IBA)

85	VaccinesIBA 12/2022 - 12/2003
71	Antiviral Agents (Antivirals)IBA 01/2022 - 12/2002
69	Proteins (Proteins, Gene)FDA Link 05/2022 - 07/2005
69	AntibodiesIBA 03/2022 - 02/2003
62	Monoclonal AntibodiesIBA 10/2022 - 03/2005
34	InterferonsIBA 10/2022 - 01/2003
32	Neutralizing AntibodiesIBA 03/2022 - 03/2006
29	EpitopesIBA 01/2022 - 05/2005
25	Interferon Type IIBA 01/2022 - 09/2008
22	CytokinesIBA 01/2022 - 09/2008
21	AntigensIBA 01/2022 - 12/2003
21	RNA (Ribonucleic Acid)IBA 01/2022 - 12/2002
18	Immunoglobulin G (IgG)IBA 12/2020 - 12/2003
16	Complement System Proteins (Complement)IBA 01/2022 - 01/2003
14	Glycoproteins (Glycoprotein)IBA 01/2022 - 09/2005
11	ChemokinesIBA 01/2022 - 09/2005
10	Messenger RNA (mRNA)IBA 02/2022 - 07/2013
10	Viral RNAIBA 12/2020 - 12/2002
9	mRNA VaccinesIBA 02/2022 - 01/2017
9	Transcription Factors (Transcription Factor)IBA 11/2017 - 09/2011
9	Immunoglobulin M (IgM)IBA 07/2015 - 02/2003
8	LigandsIBA 01/2021 - 09/2007
7	Broadly Neutralizing AntibodiesIBA 01/2022 - 01/2016
7	Peptides (Polypeptides)IBA 01/2020 - 01/2006
7	Interferon-betaIBA 12/2015 - 03/2005
6	DNA (Deoxyribonucleic Acid)IBA 10/2020 - 03/2005
6	Phosphotransferases (Kinase)IBA 06/2020 - 12/2011
5	Interferon LambdaIBA 01/2021 - 04/2015
5	Blocking AntibodiesIBA 01/2018 - 02/2013
5	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2012 - 09/2008
5	IgG Receptors (Fc gamma RI)IBA 10/2009 - 02/2006
4	Pharmaceutical PreparationsIBA 01/2022 - 01/2017
4	N-(2-cyanoethylene)urea (BA 1)IBA 01/2022 - 01/2022
4	N-methyl-valyl-amiclenomycin (BA 2)IBA 01/2022 - 01/2022
4	SARS-CoV-2 spike proteinIBA 01/2022 - 03/2021
4	EnzymesIBA 11/2020 - 11/2008
4	Explosive Agents (Explosives)IBA 01/2020 - 08/2014
4	Interferon Regulatory FactorsIBA 10/2014 - 09/2008
4	LectinsIBA 07/2011 - 10/2009
3	2019-nCoV Vaccine mRNA-1273IBA 02/2022 - 01/2022
3	COV2-2130IBA 01/2022 - 01/2020
3	Biological ProductsIBA 01/2022 - 12/2019
3	COVID-19 VaccinesIBA 10/2021 - 12/2020
3	FurinIBA 01/2021 - 11/2011
3	Polysaccharides (Glycans)IBA 11/2020 - 08/2010
3	Anti-Bacterial Agents (Antibiotics)IBA 01/2020 - 01/2015
3	LipidsIBA 10/2019 - 01/2017
3	Interferon alpha-beta Receptor (Receptor, Interferon alpha beta)IBA 01/2019 - 09/2015
3	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2017 - 05/2006
3	c-Mer Tyrosine KinaseIBA 01/2017 - 12/2015
3	Pattern Recognition ReceptorsIBA 10/2015 - 11/2013
3	Mannose-Binding Lectin (Mannan-Binding Lectin)IBA 03/2011 - 08/2010
2	Angiotensin-Converting Enzyme 2IBA 12/2022 - 01/2021
2	K-18 conjugate (K18)IBA 12/2022 - 11/2020
2	JIB-04IBA 01/2022 - 06/2021
2	Immunoglobulins (Immunoglobulin)IBA 01/2022 - 11/2008
2	Mesalamine (Mesalazine)FDA LinkGeneric 01/2022 - 08/2021
2	Influenza Vaccines (Influenza Vaccine)FDA Link 01/2022 - 12/2021
2	COV2-2196IBA 01/2022 - 01/2020
2	Combined VaccinesIBA 11/2021 - 01/2020
2	ImmunosorbentsIBA 11/2020 - 01/2015
2	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 11/2020 - 11/2020
2	Keratin-18 (Keratin 18)IBA 11/2020 - 07/2020
2	apilimodIBA 06/2020 - 01/2020
2	vacuolin-1IBA 06/2020 - 01/2020

Therapy/Procedure

54	Therapeutics 12/2022 - 12/2002
3	Intranasal Administration 01/2021 - 10/2020